Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Subscription Offers
  • Contact
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Subscription Offers
  • Contact
Pipeline News and Updates
Picture

Update for September 15, 2020

9/15/2020

 
Regulatory Update
 
An FDA review of Mallinckrodt’s terlipressin questioned whether clinical data on hepatorenal syndrome type 1 reversal, as demonstrated by a decrease in serum creatinine, demonstrated decreased mortality, need for dialysis or intensive care days. However, the FDA Cardiovascular and Renal Drugs Advisory Committee voted 8-7 to recommend approval in July 2020. The FDA was not convinced and rejected the NDA for terlipressin and requested data to support a positive risk-benefit profile for terlipressin for HRS-1 patients in September 2020.
 
The FDA granted BeyondSpring’s plinabulin a Breakthrough Therapy Designation for the prevention of chemotherapy-induced neutropenia.
 
The FDA requested that Sarepta use a different potency assay when manufacturing its microdystrophin gene therapy, before using the drug in a Phase III trial.
 
The EMA requested 52-week data for 134 patients enrolled in a Phase III trial of BioMarin’s valoctocogene roxaparvovec for the treatment of Hemophilia A.
 
Announced Research Updates
 
Merck announced that gefapixant 45 mg BID reduced the 24-hour coughs per hour average 18.45% more than placebo in the 12-week, 730 patient, Phase III, COUGH-1 trial and by 14.64% more than placebo in the 24-week, 1,314 patient, Phase III, COUGH-2 trial in patients with refractory or unexplained chronic cough. Treatment with gefapixant 15 mg BID did not differ from placebo in neither the COUGH-1 nor COUGH-2 trials. Taste-related adverse effects were frequent with the 45 mg dose with an incidence of 58% in COUGH-1 and 68.6% in COUGH-2.
 
Corbus announced that in the 52-week, 365 patient, Phase III, RESOLVE-1 trial, treatment with lenabasum did not improve the American College of Rheumatology Combined Response Index for Systemic Sclerosis (ACR CRISS) scores compared to placebo in patients with diffuse cutaneous systemic sclerosis.
 
Gilead and Galapagos announced that in the 156-week, 739 patient, Phase II, DARWIN 3 trial (extension trial for Darwin I and II), there was an increase in infections with filgotinib, but no other safety issues.
 
Published Research Updates
 
In a 52-week, 121 patient, Phase III trial, treatment with vosoritide increased annualized growth velocity by 1.57 cm/year more than placebo in children (ages 5 to 18) with achondroplasia.
 
In the 24-week, 256 patient, Phase II, WILLOW trial, treatment with brensocatib resulted in the time to the first exacerbation of 134 days with 10 mg and 96 days with 25 mg compared to 67 days with placebo in patients with non-cystic fibrosis bronchiectasis
 
In the 266 patient, Phase III FRESCO trial, the most common adverse events with fruquintinib were hypertension, palmar-plantar erythrodysesthesia syndrome and proteinuria.
 
In the 679 patient, Phase III TARGET trial, 91.3% of patients treated with ceftobiprole achieved a 20% or more reduction from baseline in lesion size at 48 to 72 hours compared to 88.1% of patients treated with vancomycin plus aztreonam in patients with acute bacterial skin and skin structure infection.


Comments are closed.
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.